Santhera Pharmaceuticals announced that Thomas Meier, Chief Scientific Officer of Santhera, has been honored with the prestigious BioValley Basel Award 2007 "s'Goldig Läggerli" for his contributions to the greater Basel area, his merits in advancing science in the field of neuromuscular diseases and for his successful founding of MyoContract AG, one of the two predecessor companies that in 2004 combined businesses to form today's Santhera.
At the award ceremony, Rolf Rolli, Vice President of BioValley Basel, praised Thomas Meier as an outstanding scientist and example for other ambitious researchers: "Thomas Meier was infected with the entrepreneurial virus during his postdoctoral research stay in the U. S. and has been addicted to this spirit ever since. Back in Switzerland, he founded MyoContract as the first life sciences spin-off from the Biozentrum of the University of Basel. In 2004, at the creation of Santhera, he fostered a greater vision as an entrepreneur in which he became Chief Scientific Officer of the new company to focus on his main strengths, which are the scientific work and the understanding of neuromuscular biological processes."
The BioValley Basel Association created the BioValley Basel Award in 2002 with the purpose of honoring outstanding contributions to the Life Sciences in the BioValley. With the "Goldig Läggerli" award, the jury, consisting of the Board of BioValley Basel, pays tribute to persons who have had a substantial and lasting impact on Life Sciences in science, medicine, business and public policy in the greater Basel area. Previous prizewinners include the founding team of Actelion, Prof Dr Hans-Joachim Güntherodt and Prof G Schatz (University of Basel), Dr Jürg Meier (Novartis Venture Fund) and Dr h .c. Georg H. Endress (Endress+Hauser).